Dose escalation can maximize therapeutic potential of sunitinib in patients with metastatic renal cell carcinoma
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Dose escalation can maximize therapeutic potential of sunitinib in patients with metastatic renal cell carcinoma ; volume:18 ; number:1 ; day:15 ; month:3 ; year:2018 ; pages:1-12 ; date:12.2018
BMC cancer ; 18, Heft 1 (15.3.2018), 1-12, 12.2018
- Creator
-
Maráz, Anikó
- Contributor
-
Cserháti, Adrienn
Uhercsák, Gabriella
Szilágyi, Éva
Varga, Zoltán
Révész, János
Kószó, Renáta
Varga, Linda
Kahán, Zsuzsanna
SpringerLink (Online service)
- DOI
-
10.1186/s12885-018-4209-9
- URN
-
urn:nbn:de:1111-201805242648
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:37 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Maráz, Anikó
- Cserháti, Adrienn
- Uhercsák, Gabriella
- Szilágyi, Éva
- Varga, Zoltán
- Révész, János
- Kószó, Renáta
- Varga, Linda
- Kahán, Zsuzsanna
- SpringerLink (Online service)
Other Objects (12)
Ιmpact of sunitinib-induced hypothyroidism on survival of patients with metastatic renal cancer
Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib
Sunitinib-induced hypothyroidism predicts progression-free survival in metastatic renal cell carcinoma patients
Macrocytosis during sunitinib treatment predicts progression-free survival in patients with metastatic renal cell carcinoma
Sunitinib Rechallenge After Other Targeted Therapies in Metastatic Renal Cell Carcinoma Patients: A Single-Center, Retrospective Study
Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers
Metastatic collecting duct carcinoma of the kidney treated with sunitinib
Survival Benefits of Second-line Axitinib Versus Everolimus After First Line Sunitinib Treatment in Metastatic Renal Cell Carcinoma
When tyrosine kinase inhibitor sunitinib can be discontinued in metastatic renal cell carcinoma to pancreas: a case report
Predictive value of C-reactive protein in patients treated with sunitinib for metastatic clear cell renal cell carcinoma
Enhanced YB1/EphA2 axis signaling promotes acquired resistance to sunitinib and metastatic potential in renal cell carcinoma
Combined high dose radiation and pazopanib in metastatic renal cell carcinoma: a phase I dose escalation trial
Ιmpact of sunitinib-induced hypothyroidism on survival of patients with metastatic renal cancer
Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib
Sunitinib-induced hypothyroidism predicts progression-free survival in metastatic renal cell carcinoma patients
Macrocytosis during sunitinib treatment predicts progression-free survival in patients with metastatic renal cell carcinoma
Sunitinib Rechallenge After Other Targeted Therapies in Metastatic Renal Cell Carcinoma Patients: A Single-Center, Retrospective Study
Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers
Metastatic collecting duct carcinoma of the kidney treated with sunitinib
Survival Benefits of Second-line Axitinib Versus Everolimus After First Line Sunitinib Treatment in Metastatic Renal Cell Carcinoma
When tyrosine kinase inhibitor sunitinib can be discontinued in metastatic renal cell carcinoma to pancreas: a case report
Predictive value of C-reactive protein in patients treated with sunitinib for metastatic clear cell renal cell carcinoma
Enhanced YB1/EphA2 axis signaling promotes acquired resistance to sunitinib and metastatic potential in renal cell carcinoma
Combined high dose radiation and pazopanib in metastatic renal cell carcinoma: a phase I dose escalation trial
Ιmpact of sunitinib-induced hypothyroidism on survival of patients with metastatic renal cancer
Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib
Sunitinib-induced hypothyroidism predicts progression-free survival in metastatic renal cell carcinoma patients
Macrocytosis during sunitinib treatment predicts progression-free survival in patients with metastatic renal cell carcinoma
Sunitinib Rechallenge After Other Targeted Therapies in Metastatic Renal Cell Carcinoma Patients: A Single-Center, Retrospective Study
Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers
Metastatic collecting duct carcinoma of the kidney treated with sunitinib
Survival Benefits of Second-line Axitinib Versus Everolimus After First Line Sunitinib Treatment in Metastatic Renal Cell Carcinoma
When tyrosine kinase inhibitor sunitinib can be discontinued in metastatic renal cell carcinoma to pancreas: a case report
Predictive value of C-reactive protein in patients treated with sunitinib for metastatic clear cell renal cell carcinoma
Enhanced YB1/EphA2 axis signaling promotes acquired resistance to sunitinib and metastatic potential in renal cell carcinoma